{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T17:52:22Z","timestamp":1791568342500,"version":"4.3.4"},"reference-count":41,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T00:00:00Z","timestamp":1683849600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>A series of indazole derivatives were designed and synthesized by molecular hybridization strategy, and these compounds were evaluated the inhibitory activities against human cancer cell lines of lung (A549), chronic myeloid leukemia (K562), prostate (PC-3), and hepatoma (Hep-G2) by methyl thiazolyl tetrazolium (MTT) colorimetric assay. Among these, compound 6o exhibited a promising inhibitory effect against the K562 cell line with the IC50 (50% inhibition concentration) value of 5.15 \u00b5M, and this compound showed great selectivity for normal cell (HEK-293, IC50 = 33.2 \u00b5M). Moreover, compound 6o was confirmed to affect apoptosis and cell cycle possibly by inhibiting Bcl2 family members and the p53\/MDM2 pathway in a concentration-dependent manner. Overall, this study indicates that compound 6o could be a promising scaffold to develop an effective and low-toxic anticancer agent.<\/jats:p>","DOI":"10.3390\/ijms24108686","type":"journal-article","created":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T10:49:51Z","timestamp":1683888591000},"page":"8686","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Design, Synthesis and Antitumor Activity of 1H-indazole-3-amine Derivatives"],"prefix":"10.3390","volume":"24","author":[{"given":"Congyu","family":"Wang","sequence":"first","affiliation":[{"name":"College of Pharmacy, Guizhou University, Guiyang 550025, China"},{"name":"Guizhou Engineering Laboratory for Synthetic Drugs, Guizhou University, Guiyang 550025, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Zhu","sequence":"additional","affiliation":[{"name":"Center for Research and Development of Fine Chemicals, Guizhou University, Guiyang 550025, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuesha","family":"Long","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Guizhou University, Guiyang 550025, China"},{"name":"Guizhou Engineering Laboratory for Synthetic Drugs, Guizhou University, Guiyang 550025, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Wang","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Guizhou University, Guiyang 550025, China"},{"name":"Guizhou Engineering Laboratory for Synthetic Drugs, Guizhou University, Guiyang 550025, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenchao","family":"Wang","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Guizhou University, Guiyang 550025, China"},{"name":"Guizhou Engineering Laboratory for Synthetic Drugs, Guizhou University, Guiyang 550025, China"},{"name":"Center for Research and Development of Fine Chemicals, Guizhou University, Guiyang 550025, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guiping","family":"Ouyang","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Guizhou University, Guiyang 550025, China"},{"name":"Guizhou Engineering Laboratory for Synthetic Drugs, Guizhou University, Guiyang 550025, China"},{"name":"Center for Research and Development of Fine Chemicals, Guizhou University, Guiyang 550025, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,5,12]]},"reference":[{"key":"ref_1","first-page":"1","article-title":"Cancer statistics: Updated cancer burden in China Preface","volume":"27","author":"Chen","year":"2015","journal-title":"Chin. J. Cancer Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ejmech.2017.07.033","article-title":"Recent advances (2015\u20132016) in anticancer hybrids","volume":"142","author":"Kerru","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1002\/tcr.201600020","article-title":"Transition metal-involving synthesis and utilization of N-containing heterocycles: Exploration of nitrogen sources","volume":"16","author":"Gao","year":"2016","journal-title":"Chem. Rec."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.ejmech.2014.11.029","article-title":"Synthesis of indazole motifs and their medicinal importance: An overview","volume":"90","author":"Gaikwad","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1080\/13543776.2018.1472240","article-title":"Indazole derivatives and their therapeutic applications: A patent review (2013\u20132017)","volume":"28","author":"Denya","year":"2018","journal-title":"Expert. Opin. Ther. Pat."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1134\/S1070363218110233","article-title":"Synthesis and Evaluation of Anticancer Activity of Indazole Derivatives","volume":"88","author":"Reddy","year":"2018","journal-title":"Russ. J. Gen. Chem."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s00044-020-02665-7","article-title":"Indazole scaffold: A generalist for marketed and clinical drugs","volume":"30","author":"Cao","year":"2020","journal-title":"Med. Chem. Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1177\/1087057111414902","article-title":"Benzotriazoles and indazoles are scaffolds with biological activity against Entamoeba histolytica","volume":"16","author":"Lopez","year":"2011","journal-title":"J. Biomol. Screen."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1007\/s40265-019-01177-y","article-title":"Entrectinib: First Global Approval","volume":"79","author":"Keam","year":"2019","journal-title":"Drugs"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"4632","DOI":"10.1021\/jm800566m","article-title":"Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor","volume":"51","author":"Harris","year":"2008","journal-title":"J. Med. Chem."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1093\/jjco\/hyy053","article-title":"Drug review: Pazopanib","volume":"48","author":"Miyamoto","year":"2018","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1007\/s40265-017-0752-y","article-title":"Niraparib: First Global Approval","volume":"77","author":"Scott","year":"2017","journal-title":"Drugs."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s00280-011-1740-7","article-title":"A novel multi-targeted tyrosine kinase inhibitor, linifanib (ABT-869), produces functional and structural changes in tumor vasculature in an orthotopic rat glioma model","volume":"69","author":"Luo","year":"2012","journal-title":"Cancer. Chemother. Pharmacol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1200\/JCO.2017.35.6_suppl.464","article-title":"A novel strategy for axitinib dosing in the treatment of metastatic renal cell carcinoma","volume":"35","author":"Doherty","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1080\/17425255.2017.1396317","article-title":"Granisetron: A review of pharmacokinetics and clinical experience in chemotherapy induced-nausea and vomiting","volume":"13","author":"Spartinou","year":"2017","journal-title":"Expert. Opin. Drug. Metab. Toxicol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"5457","DOI":"10.1007\/s11164-015-2379-5","article-title":"Mechanochemical synthesis of cyclohexenones and indazoles as potential antimicrobial agents","volume":"42","year":"2016","journal-title":"Res. Chem. Intermed."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"106412","DOI":"10.1016\/j.bioorg.2023.106412","article-title":"1H-Indazoles derivatives targeting PI3K\/AKT\/mTOR pathway: Synthesis, anti-tumor effect and molecular mechanism","volume":"133","author":"Wang","year":"2023","journal-title":"Bioorg. Chem."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"6934","DOI":"10.1021\/jm100555f","article-title":"Expanding the diversity of allosteric bcr-abl inhibitors","volume":"53","author":"Deng","year":"2010","journal-title":"J. Med. Chem."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1021\/acsmedchemlett.8b00487","article-title":"Molecular Basis for the Selective Inhibition of Histone Deacetylase 6 by a Mercaptoacetamide Inhibitor","volume":"9","author":"Porter","year":"2018","journal-title":"Med. Chem. Lett."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1158\/1535-7163.MCT-09-0629","article-title":"Pharmacokinetics-pharmacodynamics and antitumor activity of mercaptoacetamide-based histone deacetylase inhibitors","volume":"8","author":"Konsoula","year":"2009","journal-title":"Mol. Cancer. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1021\/acsmedchemlett.5b00303","article-title":"Thiol-Based Potent and Selective HDAC6 Inhibitors Promote Tubulin Acetylation and T-Regulatory Cell Suppressive Function","volume":"6","author":"Segretti","year":"2015","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1016\/j.ejmech.2011.02.057","article-title":"Discovery, synthesis, and investigation of the antitumor activity of novel piperazinyl pyrimidine derivatives","volume":"46","author":"Shallal","year":"2011","journal-title":"Eur. J. Med. Chem."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13045-018-0624-2","article-title":"Past, present, and future of Bcr-Abl inhibitors: From chemical development to clinical efficacy","volume":"11","author":"Rossari","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"590","DOI":"10.6023\/cjoc202107049","article-title":"Synthesis and Antitumor Activity of Novel 5- and 6-Substituted Indazole Derivatives","volume":"42","author":"Wu","year":"2022","journal-title":"Chin. J. Org. Chem."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"5258","DOI":"10.1016\/j.bmcl.2015.09.052","article-title":"Discovery of 3,5-substituted 6-azaindazoles as potent pan-Pim inhibitors","volume":"25","author":"Hu","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"4458","DOI":"10.1021\/acs.jmedchem.7b00418","article-title":"Discovery of 5-Azaindazole (GNE-955) as a Potent Pan-Pim Inhibitor with Optimized Bioavailability","volume":"60","author":"Wang","year":"2017","journal-title":"J. Med. Chem."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"112710","DOI":"10.1016\/j.ejmech.2020.112710","article-title":"Design, synthesis, and biological evaluations of novel 3-amino-4-ethynyl indazole derivatives as Bcr-Abl kinase inhibitors with potent cellular antileukemic activity","volume":"207","author":"Jin","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ejmech.2019.05.091","article-title":"Discovery of novel Bcr-Abl (T315I) inhibitors with flexible linker. Part 1: Confirmation optimization of phenyl-1H-indazol-3-amine as hinge binding moiety","volume":"178","author":"Pan","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"4508","DOI":"10.3390\/molecules17044508","article-title":"The Suzuki Reaction Applied to the Synthesis of Novel Pyrrolyl and Thiophenyl Indazoles","volume":"17","author":"Migliorini","year":"2012","journal-title":"Molecules"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.1021\/jm800219f","article-title":"The many roles for fluorine in medicinal chemistry","volume":"51","author":"Hagmann","year":"2008","journal-title":"J. Med. Chem."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.drudis.2012.03.014","article-title":"Fluorine local environment: From screening to drug design","volume":"17","author":"Vulpetti","year":"2012","journal-title":"Drug. Discov. Today."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1021\/acschembio.6b00315","article-title":"Harnessing Fluorine-Sulfur Contacts and Multipolar Interactions for the Design of p53 Mutant Y220C Rescue Drugs","volume":"11","author":"Bauer","year":"2016","journal-title":"ACS Chem. Biol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"7643","DOI":"10.1039\/C5OB00778J","article-title":"Design, synthesis and biological evaluation of novel FGFR inhibitors bearing an indazole scaffold","volume":"13","author":"Liu","year":"2015","journal-title":"Org. Biomol. Chem."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"9030","DOI":"10.1038\/sj.onc.1207116","article-title":"Control of apoptosis by p53","volume":"22","author":"Fridman","year":"2003","journal-title":"Oncogene"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/nrc864","article-title":"Live or let die: The cell\u2019s response to p53","volume":"2","author":"Vousden","year":"2002","journal-title":"Nat. Rev. Cancer."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ejmech.2019.05.018","article-title":"The past, present and future of potential small-molecule drugs targeting p53-MDM2\/MDMX for cancer therapy","volume":"176","author":"Liu","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0092-8674(00)81871-1","article-title":"p53, the cellular gatekeeper for growth and division","volume":"88","author":"Levine","year":"1997","journal-title":"Cell"},{"key":"ref_38","first-page":"4855","article-title":"Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis","volume":"54","author":"Greenblatt","year":"1994","journal-title":"Cancer. Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1002\/j.1460-2075.1991.tb07676.x","article-title":"Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line","volume":"10","author":"Fakharzadeh","year":"1991","journal-title":"EMBO J."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/358080a0","article-title":"Amplification of a gene encoding a p53-associated protein in human sarcomas","volume":"358","author":"Oliner","year":"1992","journal-title":"Nature"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"15608","DOI":"10.1073\/pnas.95.26.15608","article-title":"Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis","volume":"95","author":"Jones","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/10\/8686\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:33:49Z","timestamp":1760124829000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/10\/8686"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,12]]},"references-count":41,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,5]]}},"alternative-id":["ijms24108686"],"URL":"https:\/\/doi.org\/10.3390\/ijms24108686","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,12]]}}}